Form 4: Acumen COO Sells Shares for Tax Obligations

Acumen Pharmaceuticals' Chief Operating Officer, Russell Barton, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Russell Barton, Chief Operating Officer of Acumen Pharmaceuticals, Inc. (ABOS), reported the sale of a total of 9,318 shares of common stock.
• The sales occurred on January 5, 2026 (4,000 shares), January 6, 2026 (3,618 shares), and January 7, 2026 (1,700 shares).
• These transactions were automatic 'sell to cover' sales to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
• The sales were executed pursuant to Rule 10b5-1 trading plans adopted by Mr. Barton on August 30, 2024, and June 25, 2025.
• Following these reported transactions, Mr. Barton beneficially owns 126,799 shares of Acumen Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The transactions are routine 'sell to cover' sales for tax purposes related to RSU vesting, executed under pre-arranged 10b5-1 plans, and do not indicate a change in management's outlook or a significant positive/negative event.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Minimal direct impact on shareholders as these are routine tax-related sales by an executive, not indicative of a change in company fundamentals or executive sentiment.

Key Dates

Recommendation

The reported transactions are routine 'sell to cover' sales by an executive to satisfy tax obligations upon the vesting of restricted stock units. These sales were executed under pre-arranged Rule 10b5-1 trading plans and do not reflect a discretionary decision by the executive to sell shares based on a change in company outlook. Therefore, this filing alone does not provide a basis for a change in investment recommendation.

Keywords

Acumen Pharmaceuticals, ABOS, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Rule 10b5-1, Russell Barton, Chief Operating Officer